UK Markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1602
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.3582%)
     
  • BTC-GBP

    34,479.12
    -930.61 (-2.63%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Miners, Ashtead support UK shares; AstraZeneca gains

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(For a live blog on European stocks, type LIVE/ in an Eikon news window)

* FTSE 100 up 0.1%, FTSE 250 down 0.2%

* AstraZeneca biggest boost to FTSE 100

* Ashtead rises after annual results

* Focus shifting to Fed policy meeting

June 18 (Reuters) - London's FTSE 100 edged higher on Tuesday with tool hire firm Ashtead gaining after an upbeat earnings report and miners boosted by a rise in copper prices driven by expectations of a global shortfall in production.

The miner-heavy main index was up 0.1% while the FTSE 250 midcap index lost 0.2% by 0708 GMT.

Ashtead rose nearly 3%, topping the FTSE 100 leader-board, while miners were up 1% as a key mine in Chile halved output due to a strike.

Drugmaker AstraZeneca was the biggest boost to the FTSE 100 with a 1.1% rise after its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission. Rival GlaxoSmithKline also climbed.

Market focus is gradually shifting to a two-day meeting of the U.S. Federal Reserve, with market pricing showing investors expect Wednesday's policy statement to open the way to a cut in interest rates by the central bank next month. (Reporting by Muvija M in Bengaluru; editing by Patrick Graham)